Use the hyperlinks, where available to access additional clinical trial information.
A Phase III, Open-Label, Randomized Study of Atezolizumab in Combination With Bevacizumab Compared With Sorafenib in Patients With Untreated Locally Advanced or Metastatic Hepatocellular Carcinoma
Participants will be randomized into one of two arms. In the experimental arm, participants will receive Atezolizumab + Bevacizumab until unacceptable toxicity or loss of clinical benefit as determined by the investigator. Atezolizumab will be administered by IV, 1200 mg on day 1 of each 21 day cycle; Bevacizumab will be administered by IV, 15 mg/kg on day 1 of each 21 day cycle. In the comparator arm, participants will Participants will receive Sorafenib until unacceptable toxicity or loss of clinical benefit as determined by the investigator. Sorafenib will be administered by mouth, 400 mg twice per day, on days 1-21 of each 21-day cycle.